id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0081-0008,FDA,FDA-2012-D-0081,Guidance on Investigational New Drug Applications for Positron Emission Tomography Drugs,Notice,Notice of Availability,2012-12-04T05:00:00Z,2012,12,2012-12-04T05:00:00Z,,2012-12-04T16:52:03Z,2012-29163,0,0,090000648117e397
FDA-2012-D-0081-0009,FDA,FDA-2012-D-0081,Guidance on Investigational New Drug Applications for Positron Emission Tomography Drugs,Other,Guidance,2012-12-04T05:00:00Z,2012,12,2012-12-04T05:00:00Z,,2024-11-12T05:09:54Z,,1,0,090000648117e734
FDA-2012-D-0081-0002,FDA,FDA-2012-D-0081,Draft Guidance; Investigational New Drug Applications for Positron Emission Tomography Drugs,Other,Guidance,2012-02-14T05:00:00Z,2012,2,2012-02-14T05:00:00Z,,2019-10-21T14:18:48Z,,0,0,0900006480fb4cb7
FDA-2012-D-0081-0001,FDA,FDA-2012-D-0081,Draft Guidance; Availability: Investigational New Drug Applications for Positron Emission Tomography Drugs,Notice,Notice of Availability,2012-02-14T05:00:00Z,2012,2,2012-02-14T05:00:00Z,2012-05-15T03:59:59Z,2012-05-15T12:01:11Z,2012-03319,0,0,0900006480fb55ef